Oxford, UK and Cambridge, MA – (July 23, 2024) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced today the completion of enrollment in its Phase I trial of SPYVLP01, a vaccine candidate targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology. […] The post SpyBiotech Announces the Completion of Enrollment in Phase I Trial of SPYVLP01 Targeting Human Cytomegalovirus (HCMV) first appeared on SpyBiotech .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules